在心力衰竭中限制流体与不限制:全面分析
Siddharth Pravin Agrawal1, Pankti Maniyar2, Divya Nagesh Sharma3
1From the Department of Internal Medicine, New York Medical College/Landmark Medical Center, Woonsocket, RI.
Cardiology in review
|August 13, 2025
概括
严格的液体限制可能对稳定的心力衰竭 (HF) 患者没有好处,并可能降低生活质量. 对流体管理的个性化方法正在成为HF护理的更好的策略.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内部医学 内部医学
背景情况:
- 心力衰竭 (HF) 是一种复杂的综合征,通常因流体过载而复杂化,导致呼吸障碍和等症状.
- 神经激素调节失调,包括氨酸- ангиотензин-阿尔多斯特系统,驱动HF的液体积累.
- 从历史上看,液体限制一直是HF控制体积过载的主要管理策略.
研究的目的:
- 评估稳定心力衰竭患者严格限制流体的临床益处和对生活质量的影响.
- 探索心力衰竭护理中流体管理的不断发展的理解.
- 突出需要个性化流体管理策略在HF.
主要方法:
- 审查最近的研究,包括FRESH-UP试验,检查心力衰竭中的液体限制.
- 分析目前的指导方针和新出现的关于高频流体管理的证据.
- 考虑影响流体管理决策的患者特定因素.
主要成果:
- FRESH-UP试验表明,严格的液体限制可能不会为稳定的HF患者提供显著的临床益处.
- 严格的液体限制可能会对生活质量产生负面影响,因为口渴和不适会增加.
- 目前的指导方针建议针对特定HF患者亚组进行选择性流体限制.
结论:
- 新出现的证据支持在心力衰竭中采取更个性化的流体管理方法.
- 根据患者因素 (如功能类别和喷射分数) 量身定制流体管理至关重要.
- 需要进一步的研究来优化流体管理协议,以改善HF患者的治疗结果和生活质量.
更多相关视频
05:16Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
214
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
8.6K
相关概念视频
01:22Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:22Heart Failure Drugs: Diuretics
484
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
484
01:30Heart Failure VII: Nursing Interventions
139
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
139
01:30Heart Failure IV: Classification and Diagnostic Evaluation
32
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
32
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
508
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
508